A few years ago, following early encouraging data, two KRAS G12C inhibitors came into the spotlight at the American Society of Clinical Oncology meeting in Chicago. While new therapies are not exceptional in pharma, what made these drugs special was that scientists had been trying to develop a drug specifically for this target for a very long time.

With updated data on both drugs, one of which is already approved, the market has been forecasting billion-dollar sales for these therapies in the near future. In this month’s issue, we take a look at their clinical significance and whether the hype is warranted.

Also, in this issue, features delve into the early research on nanorobots and how they could address drug delivery challenges, and how foreign direct investments in nucleic acid therapies have burgeoned in the recent past despite a general investment slowdown due to the pandemic.

All this, and the latest pharma industry news, comment, data, and analysis from GlobalData.

Manasi Vaidya, editor